TRDA - Entrada Therapeutics, Inc. Stock Price, Fair Value and News

$10.05+0.20 (+2.03%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

TRDA Price Action

Last 7 days

-0.3%

Last 30 days

48.2%

Last 90 days

92.5%

Trailing 12 Months

-50.2%

TRDA RSI Chart

TRDA Valuation

Market Cap

384.1M

Price/Earnings (Trailing)

-3.71

Price/Sales (Trailing)

6.24

Price/Free Cashflow

-2.96

TRDA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

TRDA Fundamentals

TRDA Revenue

Revenue (TTM)

61.5M

Rev. Growth (Yr)

-91.75%

Rev. Growth (Qtr)

-17.23%

TRDA Earnings

Earnings (TTM)

-103.5M

Earnings Growth (Yr)

-214.52%

Earnings Growth (Qtr)

-2.39%

TRDA Profitability

Return on Equity

-30.36%

Return on Assets

-25.06%

Free Cashflow Yield

-33.79%

TRDA Investor Care

Shares Dilution (1Y)

2.14%

Diluted EPS (TTM)

-2.64

TRDA Alerts

1 major insider buys and 2 major insider sales recently.
Big fall in Revenue (Y/Y)
Big fall in earnings (Y/Y)
Losses in recent quarter

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	172.2M	79.5M	61.5M	0
2024	162.9M	239.4M	215.2M	210.8M
2023	0	0	0	129.0M

Get all data in R, Python etc through our Historical Stock Data APIs

About Entrada Therapeutics, Inc.

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead therapeutic candidates, which include ENTR-601-44 and ENTR-601-45, which are in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1; ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy; and ENTR-701, which is in preclinical trail for the treatment of myotonic dystrophy type 1. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

CEO	Mr. Dipal Doshi
WEBSITE	entradatx.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	131

Entrada Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Entrada Therapeutics, Inc.? What does TRDA stand for in stocks?

TRDA is the stock ticker symbol of Entrada Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Entrada Therapeutics, Inc. (TRDA)?

As of Wed Dec 03 2025, market cap of Entrada Therapeutics, Inc. is 384.1 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TRDA stock?

You can check TRDA's fair value in chart for subscribers.

Is Entrada Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether TRDA is over valued or under valued. Whether Entrada Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Entrada Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TRDA.

What is Entrada Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, TRDA's PE ratio (Price to Earnings) is -3.71 and Price to Sales (PS) ratio is 6.24. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TRDA PE ratio will change depending on the future growth rate expectations of investors.